Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo

Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility Novel second generation analogs of eribulin. Part III: Blood–brain barrier permeability and in vivo activity in a brain tumor model Atom-based enumeration: New eribulin analogues with low susceptibility to P-glycoprotein-mediated drug efflux Effects of Isoprenoid Analogues ofSDB-Ethylenediamine on Multidrug Resistant Tumor Cells Alone and in Combination with Chemotherapeutic Drugs Isomeric N,N-Bis(cyclohexanol)amine Aryl Esters:  The Discovery of a New Class of Highly Potent P-Glycoprotein (Pgp)-dependent Multidrug Resistance (MDR) Inhibitors Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 1: Erlotinib analogs Vinblastine 20′ Amides: Synthetic Analogues That Maintain or Improve Potency and Simultaneously Overcome Pgp-Derived Efflux and Resistance Structure−Activity Relationships Studies in a Series of N,N-Bis(alkanol)amine Aryl Esters as P-Glycoprotein (Pgp) Dependent Multidrug Resistance (MDR) Inhibitors Synthesis and biological evaluation of taxinine analogues as orally active multidrug resistance reversal agents in cancer